BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24037082)

  • 1. The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers.
    Landowski TH; Samulitis BK; Dorr RT
    Invest New Drugs; 2013 Dec; 31(6):1616-25. PubMed ID: 24037082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Halichondrin B amide acts as tubulin binding agent to exhibit anti-tumor efficacy in hematologic cancers.
    Li YC; Zhang R; Yang Y; Li J; Zhu K; Yao K; Liu ZG
    Int J Clin Exp Med; 2015; 8(10):19662-9. PubMed ID: 26770630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin.
    Gao F; Liang Y; Zhou P; Cheng J; Ding K; Wang Y
    Eur J Med Chem; 2019 Sep; 178():177-194. PubMed ID: 31185410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer.
    Shaw AY; Henderson MC; Flynn G; Samulitis B; Han H; Stratton SP; Chow HH; Hurley LH; Dorr RT
    J Pharmacol Exp Ther; 2009 Nov; 331(2):636-47. PubMed ID: 19657049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
    Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.
    Levrier C; Sadowski MC; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Nelson CC
    Mol Cancer Ther; 2017 Jan; 16(1):3-15. PubMed ID: 27760837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy.
    González M; Ovejero-Sánchez M; Vicente-Blázquez A; Álvarez R; Herrero AB; Medarde M; González-Sarmiento R; Peláez R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SKLB-14b, a novel oral microtubule-destabilizing agent based on hydroxamic acid with potent anti-tumor and anti-multidrug resistance activities.
    Zhang W; Yang L; Si W; Tang M; Bai P; Zhu Z; Kuang S; Liu J; Shi M; Huang J; Chen X; Li D; Wen Y; Yang Z; Xiao K; Chen L
    Bioorg Chem; 2022 Nov; 128():106053. PubMed ID: 35964504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
    Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
    Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SRC and tubulin in mucinous ovarian carcinoma.
    Liu T; Hu W; Dalton HJ; Choi HJ; Huang J; Kang Y; Pradeep S; Miyake T; Song JH; Wen Y; Lu C; Pecot CV; Bottsford-Miller J; Zand B; Jennings NB; Ivan C; Gallick GE; Baggerly KA; Hangauer DG; Coleman RL; Frumovitz M; Sood AK
    Clin Cancer Res; 2013 Dec; 19(23):6532-43. PubMed ID: 24100628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferulin C triggers potent PAK1 and p21-mediated anti-tumor effects in breast cancer by inhibiting Tubulin polymerization in vitro and in vivo.
    Yao D; Pan D; Zhen Y; Huang J; Wang J; Zhang J; He Z
    Pharmacol Res; 2020 Feb; 152():104605. PubMed ID: 31863866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity.
    Arora S; Wang XI; Keenan SM; Andaya C; Zhang Q; Peng Y; Welsh WJ
    Cancer Res; 2009 Mar; 69(5):1910-5. PubMed ID: 19223556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity.
    Magalhaes LG; Marques FB; da Fonseca MB; Rogério KR; Graebin CS; Andricopulo AD
    PLoS One; 2016; 11(8):e0160842. PubMed ID: 27508497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
    Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition.
    Viola G; Cecconet L; Leszl A; Basso G; Brun P; Salvador A; Dall'Acqua F; Diana P; Barraja P; Cirrincione G
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1235-51. PubMed ID: 19363609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells.
    Chao MW; Huang HL; HuangFu WC; Hsu KC; Liu YM; Wu YW; Lin CF; Chen YL; Lai MJ; Lee HY; Liou JP; Teng CM; Yang CR
    Oncotarget; 2017 Apr; 8(17):27772-27785. PubMed ID: 28186963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
    Toner AP; McLaughlin F; Giles FJ; Sullivan FJ; O'Connell E; Carleton LA; Breen L; Dunne G; Gorman AM; Lewis JD; Glynn SA
    Br J Cancer; 2013 Oct; 109(8):2131-41. PubMed ID: 24052043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
    Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.